Ryo Yamashita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryo Yamashita has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Masashi Niwakawa
Division of Urology, Shizuoka Cancer Center, Shizuoka, Shizuoka, Japan
12 shared publicationsHideo Shinsaka
Division of Urology, Shizuoka Cancer Center, Shizuoka, Shizuoka, Japan
10 shared publicationsMasato Matsuzaki
Division of Urology, Shizuoka Cancer Center, Shizuoka, Shizuoka, Japan
10 shared publicationsMasafumi Nakamura
Division of Urology, Shizuoka Cancer Center, Shizuoka, Shizuoka, Japan
8 shared publicationsAkifumi Notsu
Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan
6 shared publicationsTakashi Sugino
Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan
6 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (6) , e70523
Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real‐World Multicenter Study
Objective: This study aimed to evaluate the clinical relevance of early relative dose intensity (eRDI) during enfortumab vedotin (EV) monotherapy in patients with metastatic urothelial carcinoma (mUC) based on a Japanese real‐world multicenter cohort. Methods: We retrospectively analyzed 119 patients with mUC who received EV. The temporal trend of total relative dose intensity (tRDI), defined as the cumulative relative dose intensity during treatment, was assessed over the first 5 months. eRDI, calculated as the mean RDI over the initial 3 months, was also evaluated. Survival analyses were performed in 84 patients evaluable beyond the first radiographic assessment, excluding those with early progressive disease (PD). Patients were stratified by eRDI (≥ 80% vs. < 80%), and progression‐free survival (PFS) and overall survival (OS) were compared. Subgroup analyses were conducted according to the presence or absence of adverse event–related dose modification (AE‐related DM). Results: Dose intensity gradually declined during the early treatment phase. The eRDI was not significantly associated with PFS or OS in the PD‐excluded cohort ( n = 84). However, among patients without AE‐related DM ( n = 44), high eRDI was associated with significantly longer PFS (median 11.7 vs. 4.2 months; p = 0.001) and OS (not reached vs. 13.8 months; p = 0.021). No significant association was observed between eRDI and survival in patients with AE‐related DM. Conclusions: Although eRDI was not an overall significant prognostic factor, it showed clinical relevance in patients without AE‐related DM. These findings underscore the importance of preserving eRDI in patients with sufficient tolerability and support individualized dosing strategies for EV therapy.
- 2 June 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (6) , e70523
Open AccessImpact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real‐World Multicenter Study
Objective: This study aimed to evaluate the clinical relevance of early relative dose intensity (eRDI) during enfortumab vedotin (EV) monotherapy in patients with metastatic urothelial carcinoma (mUC) based on a Japanese real‐world multicenter cohort. Methods: We retrospectively analyzed 119 patients with mUC who received EV. The temporal trend of total relative dose intensity (tRDI), defined as the cumulative relative dose intensity during treatment, was assessed over the first 5 months. eRDI, calculated as the mean RDI over the initial 3 months, was also evaluated. Survival analyses were performed in 84 patients evaluable beyond the first radiographic assessment, excluding those with early progressive disease (PD). Patients were stratified by eRDI (≥ 80% vs. < 80%), and progression‐free survival (PFS) and overall survival (OS) were compared. Subgroup analyses were conducted according to the presence or absence of adverse event–related dose modification (AE‐related DM). Results: Dose intensity gradually declined during the early treatment phase. The eRDI was not significantly associated with PFS or OS in the PD‐excluded cohort ( n = 84). However, among patients without AE‐related DM ( n = 44), high eRDI was associated with significantly longer PFS (median 11.7 vs. 4.2 months; p = 0.001) and OS (not reached vs. 13.8 months; p = 0.021). No significant association was observed between eRDI and survival in patients with AE‐related DM. Conclusions: Although eRDI was not an overall significant prognostic factor, it showed clinical relevance in patients without AE‐related DM. These findings underscore the importance of preserving eRDI in patients with sufficient tolerability and support individualized dosing strategies for EV therapy.
- 29 May 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (6) , e70531
Long‐Term Clinical Outcomes of Advanced Germ Cell Tumors: Experience From 105 Patients Over 20 Years
Objectives: Limited data on metastatic germ cell tumors are available in Japan. We aimed to evaluate the long‐term cancer‐specific mortality of advanced germ cell tumors. Methods: We present the clinical outcomes of 105 patients with mediastinal or metastatic germ cell tumors, including 33 seminoma and 72 non‐seminoma, who received induction cisplatin‐based chemotherapy at our hospital between September 2002 and February 2025. We evaluated the 5‐year cancer‐specific survival, pathologic findings of residual tumor resection, and risk factors for cancer death. Results: The median follow‐up period of all patients was 63 months (interquartile range: 26–120 months). The 5‐year cancer‐specific survival was 97% in patients with seminoma and 73% in patients with non‐seminoma. Of 72 patients, 56 with non‐seminoma received residual tumor resection after chemotherapy. In terms of pathologic findings, the proportions of viable cells, teratoma, and necrosis were 25%, 30%, and 45%, respectively. The 5‐year cancer‐specific survival was 90% in 47 patients with normalized tumor markers at the time of surgery and 28% in nine patients with non‐normalized tumor markers. In multivariate analysis, non‐pulmonary visceral metastasis was the most significant risk factor associated with cancer‐related death. Conclusions: The treatment of patients with non‐seminoma who present with non‐pulmonary visceral metastases, including metastases to the liver, brain, bone, and other visceral sites, remains challenging. Although patient selection is crucial, a subset of patients with non‐normalized tumor markers at the time of salvage surgery achieved long‐term survival.
- 29 May 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (6) , e70531
Long‐Term Clinical Outcomes of Advanced Germ Cell Tumors: Experience From 105 Patients Over 20 Years
Objectives: Limited data on metastatic germ cell tumors are available in Japan. We aimed to evaluate the long‐term cancer‐specific mortality of advanced germ cell tumors. Methods: We present the clinical outcomes of 105 patients with mediastinal or metastatic germ cell tumors, including 33 seminoma and 72 non‐seminoma, who received induction cisplatin‐based chemotherapy at our hospital between September 2002 and February 2025. We evaluated the 5‐year cancer‐specific survival, pathologic findings of residual tumor resection, and risk factors for cancer death. Results: The median follow‐up period of all patients was 63 months (interquartile range: 26–120 months). The 5‐year cancer‐specific survival was 97% in patients with seminoma and 73% in patients with non‐seminoma. Of 72 patients, 56 with non‐seminoma received residual tumor resection after chemotherapy. In terms of pathologic findings, the proportions of viable cells, teratoma, and necrosis were 25%, 30%, and 45%, respectively. The 5‐year cancer‐specific survival was 90% in 47 patients with normalized tumor markers at the time of surgery and 28% in nine patients with non‐normalized tumor markers. In multivariate analysis, non‐pulmonary visceral metastasis was the most significant risk factor associated with cancer‐related death. Conclusions: The treatment of patients with non‐seminoma who present with non‐pulmonary visceral metastases, including metastases to the liver, brain, bone, and other visceral sites, remains challenging. Although patient selection is crucial, a subset of patients with non‐normalized tumor markers at the time of salvage surgery achieved long‐term survival.
- Open Access
- 9 March 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (2) , e70155
A Case of Unexpected Peritoneal Carcinomatosis From Colon Cancer Detected After Robot‐Assisted Radical Cystectomy for Advanced Bladder Cancer
Introduction: Peritoneal carcinomatosis in patients with advanced bladder cancer is a rare but lethal event following robot‐assisted radical cystectomy (RARC). We report a case of an unusual clinical course in which peritoneal dissemination of colon cancer was unexpectedly detected seven months after RARC. Case Presentation: A 67‐year‐old man underwent two courses of neoadjuvant chemotherapy and subsequent RARC with extracorporeal urinary diversion for muscle‐invasive bladder cancer. The pathological diagnosis of the RARC specimen was urothelial carcinoma in situ (ypTis). After 7 months, the patient developed small bowel obstruction and underwent laparotomy. Intraoperatively, numerous seeding nodules were observed in the pelvic cavities, involving the small intestine. Contrary to our expectation of bladder cancer recurrence, the pathological examination revealed adenocarcinoma, suggesting primary colorectal cancer. Conclusion: Peritoneal dissemination occurring shortly after RARC is often considered due to bladder cancer. However, the possibility of metastasis from other cancers must be taken into consideration.
- 9 March 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (2) , e70155
Open AccessA Case of Unexpected Peritoneal Carcinomatosis From Colon Cancer Detected After Robot‐Assisted Radical Cystectomy for Advanced Bladder Cancer
Introduction: Peritoneal carcinomatosis in patients with advanced bladder cancer is a rare but lethal event following robot‐assisted radical cystectomy (RARC). We report a case of an unusual clinical course in which peritoneal dissemination of colon cancer was unexpectedly detected seven months after RARC. Case Presentation: A 67‐year‐old man underwent two courses of neoadjuvant chemotherapy and subsequent RARC with extracorporeal urinary diversion for muscle‐invasive bladder cancer. The pathological diagnosis of the RARC specimen was urothelial carcinoma in situ (ypTis). After 7 months, the patient developed small bowel obstruction and underwent laparotomy. Intraoperatively, numerous seeding nodules were observed in the pelvic cavities, involving the small intestine. Contrary to our expectation of bladder cancer recurrence, the pathological examination revealed adenocarcinoma, suggesting primary colorectal cancer. Conclusion: Peritoneal dissemination occurring shortly after RARC is often considered due to bladder cancer. However, the possibility of metastasis from other cancers must be taken into consideration.
- 19 May 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-6
Relationship between urinary pH and efficacy of Bacillus Calmette-Guérin treatment in patients with carcinoma in situ of the bladder
Purpose Bacillus Calmette-Guérin (BCG) is the standard treatment for carcinoma in situ (CIS) in patients with urothelial bladder carcinoma. We aimed to determine whether average urinary pH before BCG instillation affects the BCG response. Methods Between August 2003 and January 2023, 203 patients with CIS received BCG treatment (Tokyo strain, 80 mg, ≥ 5 times) at our hospital. Average urinary pH was calculated by summing each urinary pH measurement before BCG instillation and dividing by the number of instillations. The Fine-Gray method was used to assess the relationship between average urinary pH (as a continuous variable) and intravesical recurrence. We also analyzed the cumulative incidence of intravesical recurrence after BCG treatment using different cutoff values for average urinary pH (median and trisection of the cohort). Results The median follow-up period was 45 months (interquartile range (IQR): 14–83 months). The median urinary pH was 6.07 (IQR: 5.68‒6.50). In multivariate analysis, average urinary pH before BCG was significantly associated with intravesical recurrence (hazard ratio: 0.53, 95% confidence interval 0.32–0.89, p = 0.017). The cumulative incidence of intravesical recurrence differed significantly when categorized by average urinary pH (median and trisection), with patients having higher urinary pH showing lower intravesical recurrence rates. Conclusion This is the first study to examine the relationship between BCG response and average urinary pH in patients with CIS. Patients with higher urinary pH had lower intravesical recurrence rates after BCG treatment.
- 19 May 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-6
Relationship between urinary pH and efficacy of Bacillus Calmette-Guérin treatment in patients with carcinoma in situ of the bladder
Purpose Bacillus Calmette-Guérin (BCG) is the standard treatment for carcinoma in situ (CIS) in patients with urothelial bladder carcinoma. We aimed to determine whether average urinary pH before BCG instillation affects the BCG response. Methods Between August 2003 and January 2023, 203 patients with CIS received BCG treatment (Tokyo strain, 80 mg, ≥ 5 times) at our hospital. Average urinary pH was calculated by summing each urinary pH measurement before BCG instillation and dividing by the number of instillations. The Fine-Gray method was used to assess the relationship between average urinary pH (as a continuous variable) and intravesical recurrence. We also analyzed the cumulative incidence of intravesical recurrence after BCG treatment using different cutoff values for average urinary pH (median and trisection of the cohort). Results The median follow-up period was 45 months (interquartile range (IQR): 14–83 months). The median urinary pH was 6.07 (IQR: 5.68‒6.50). In multivariate analysis, average urinary pH before BCG was significantly associated with intravesical recurrence (hazard ratio: 0.53, 95% confidence interval 0.32–0.89, p = 0.017). The cumulative incidence of intravesical recurrence differed significantly when categorized by average urinary pH (median and trisection), with patients having higher urinary pH showing lower intravesical recurrence rates. Conclusion This is the first study to examine the relationship between BCG response and average urinary pH in patients with CIS. Patients with higher urinary pH had lower intravesical recurrence rates after BCG treatment.
- 14 January 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Clinical outcome of BCG treatment for patients with urothelial carcinoma of the prostatic urethra: Implications for early cystectomy
Purposes This study aimed to clarify the clinical outcomes of Bacillus Calmette-Guérin (BCG) treatment in patients with urothelial carcinoma (UC) of the prostatic urethra. Methods Between August 2003 and January 2023, 428 patients with non-muscle-invasive UC received BCG treatment (Tokyo strain, 80 mg, ≥ 5 times) in our hospital; 39 had UC of the prostatic urethra. We evaluated the cumulative incidence of intravesical recurrence, progression (muscle-invasive bladder cancer [MIBC] or metastasis), and subsequent radical cystectomy after BCG treatment in patients with UC of the prostatic urethra. Results The median follow-up period was 57 months (interquartile range, 30–85 months). The exact T stage of the patients with UC of the prostatic urethra was carcinoma in situ (CIS) in 29 (27 in the prostatic urethral mucosa and two in the ductal spread), Ta in 7, Ta + CIS in 2, and T1 in 1. All 39 patients had previous or concurrent bladder cancer. Patients with UC of the prostatic urethra experienced significantly higher rates of intravesical recurrence, progression (MIBC or metastasis), and subsequent radical cystectomy than those without UC of the prostatic urethra. In the multivariate analysis, UC of the prostatic urethra was a significant risk factor for progression (hazard ratio 4.06, 95% confidence interval 1.86–8.86, p < 0.001). Conclusions This study reported the largest number of clinical outcomes after BCG treatment in patients with UC of the prostatic urethra. Concomitant UC of the prostatic urethra is a strong predictor of subsequent progression; therefore, early timing of radical cystectomy should be discussed.
- 14 January 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Clinical outcome of BCG treatment for patients with urothelial carcinoma of the prostatic urethra: Implications for early cystectomy
Purposes This study aimed to clarify the clinical outcomes of Bacillus Calmette-Guérin (BCG) treatment in patients with urothelial carcinoma (UC) of the prostatic urethra. Methods Between August 2003 and January 2023, 428 patients with non-muscle-invasive UC received BCG treatment (Tokyo strain, 80 mg, ≥ 5 times) in our hospital; 39 had UC of the prostatic urethra. We evaluated the cumulative incidence of intravesical recurrence, progression (muscle-invasive bladder cancer [MIBC] or metastasis), and subsequent radical cystectomy after BCG treatment in patients with UC of the prostatic urethra. Results The median follow-up period was 57 months (interquartile range, 30–85 months). The exact T stage of the patients with UC of the prostatic urethra was carcinoma in situ (CIS) in 29 (27 in the prostatic urethral mucosa and two in the ductal spread), Ta in 7, Ta + CIS in 2, and T1 in 1. All 39 patients had previous or concurrent bladder cancer. Patients with UC of the prostatic urethra experienced significantly higher rates of intravesical recurrence, progression (MIBC or metastasis), and subsequent radical cystectomy than those without UC of the prostatic urethra. In the multivariate analysis, UC of the prostatic urethra was a significant risk factor for progression (hazard ratio 4.06, 95% confidence interval 1.86–8.86, p < 0.001). Conclusions This study reported the largest number of clinical outcomes after BCG treatment in patients with UC of the prostatic urethra. Concomitant UC of the prostatic urethra is a strong predictor of subsequent progression; therefore, early timing of radical cystectomy should be discussed.
- 12 April 2024
- Published by Wiley in International Journal of Urology
- Vol. 31 (7) , 785-792
Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification
Objectives: We investigated the clinical outcomes of radical cystectomy without cisplatin‐based neoadjuvant chemotherapy (NAC) and identified factors affecting the effectiveness of cisplatin‐based adjuvant chemotherapy (AC).Methods: Between September 2002 and February 2020, 288 bladder cancer patients who did not receive NAC underwent radical cystectomy. We retrospectively analyzed the recurrence rates, primary recurrence sites, recurrence‐free survival (RFS), and overall survival (OS) of 115 advanced bladder cancer patients (pT3–4 or pN1–3) who were divided into the AC and observation groups. Subgroup analysis was performed, focusing on pathological stage.Results: In total, 51 patients received AC, and 64 patients were observed. The median follow‐up duration was 95 months. The recurrence rate was lower in the AC group than in the observation group (35.3% vs. 54.7%, p = 0.041). The rate of recurrences in the lymph node area (dissection site and proximal lymph nodes) was lower in the AC group (9.8% vs. 26.6%; p = 0.031). In the subgroup analysis of patients with pN1, the probability of RFS and OS was higher in the AC group than in the observation group. The hazard ratio for RFS and OS was 0.243 (95% confidence interval [CI]: 0.077–0.768) and 0.259 (95% CI: 0.082–0.816), respectively. The 5‐year RFS and OS were significantly higher in the AC group (80.0% and 79.4%) than in the observation group (35.7% and 42.9%; p < 0.008 and p < 0.012, respectively).Conclusions: AC improved RFS and OS in patients with pN1 disease who did not receive NAC and should be considered for this population.
- 12 April 2024
- Published by Wiley in International Journal of Urology
- Vol. 31 (7) , 785-792
Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification
Objectives: We investigated the clinical outcomes of radical cystectomy without cisplatin‐based neoadjuvant chemotherapy (NAC) and identified factors affecting the effectiveness of cisplatin‐based adjuvant chemotherapy (AC).Methods: Between September 2002 and February 2020, 288 bladder cancer patients who did not receive NAC underwent radical cystectomy. We retrospectively analyzed the recurrence rates, primary recurrence sites, recurrence‐free survival (RFS), and overall survival (OS) of 115 advanced bladder cancer patients (pT3–4 or pN1–3) who were divided into the AC and observation groups. Subgroup analysis was performed, focusing on pathological stage.Results: In total, 51 patients received AC, and 64 patients were observed. The median follow‐up duration was 95 months. The recurrence rate was lower in the AC group than in the observation group (35.3% vs. 54.7%, p = 0.041). The rate of recurrences in the lymph node area (dissection site and proximal lymph nodes) was lower in the AC group (9.8% vs. 26.6%; p = 0.031). In the subgroup analysis of patients with pN1, the probability of RFS and OS was higher in the AC group than in the observation group. The hazard ratio for RFS and OS was 0.243 (95% confidence interval [CI]: 0.077–0.768) and 0.259 (95% CI: 0.082–0.816), respectively. The 5‐year RFS and OS were significantly higher in the AC group (80.0% and 79.4%) than in the observation group (35.7% and 42.9%; p < 0.008 and p < 0.012, respectively).Conclusions: AC improved RFS and OS in patients with pN1 disease who did not receive NAC and should be considered for this population.
- Open Access
- 29 February 2024
- Published by Wiley in BJUI Compass
- Vol. 5 (5) , 597-603
Cumulative incidence and risk factors for recurrence of upper tract urothelial carcinoma in patients undergoing radical cystectomy
Objectives: This study aimed to evaluate the cumulative incidence of upper tract urothelial carcinoma (UTUC) recurrence and identify its risk factors in patients who underwent radical cystectomy (RC).Patients and methods: We performed RC on 385 patients between September 2002 and February 2020. After excluding 20 patients—13 with simultaneous nephroureterectomy, 6 with distal ureteral stump positivity and 1 with urachal cancer—365 patients were included in the analysis. To predict UTUC recurrence, we examined the cancer extension pattern in cystectomy specimens and categorized them into three types: cancer located only in the bladder (bladder‐only type), cancer extending to the urethra or distal ureter (one‐extension type) and cancer extending to both the urethra and distal ureter (both‐extension type). We determined hazard ratios for UTUC recurrence for each covariate, including this cancer extension pattern.Results: Of the 365 patients, 60% had the bladder‐only type, 30% had the one‐extension type and 10% had the both‐extension type. During a median follow‐up period of 72 months for survivors, UTUC recurred in 25 of the 365 patients, with cumulative incidences of 3.7% at 5 years and 8.3% at 10 years. The median interval from cystectomy to recurrence was 65 months (interquartile range: 36–92 months). In the multivariate analysis, the extension pattern was a significant predictor of UTUC recurrence. The hazard ratios for UTUC recurrence were 3.12 (95% confidence interval [CI] = 1.15–8.43, p = 0.025) for the one‐extension type and 5.96 (95% CI = 1.98–17.91, p = 0.001) for the both‐extension type compared with the bladder‐only type.Conclusions: The cancer extension pattern in cystectomy specimens is predictive of UTUC recurrence. A more extensive cancer extension in cystectomy specimens elevates the risk of subsequent UTUC recurrence. Intensive long‐term monitoring is essential, particularly for patients with the both‐extension type.
- 29 February 2024
- Published by Wiley in BJUI Compass
- Vol. 5 (5) , 597-603
Open AccessCumulative incidence and risk factors for recurrence of upper tract urothelial carcinoma in patients undergoing radical cystectomy
Objectives: This study aimed to evaluate the cumulative incidence of upper tract urothelial carcinoma (UTUC) recurrence and identify its risk factors in patients who underwent radical cystectomy (RC).Patients and methods: We performed RC on 385 patients between September 2002 and February 2020. After excluding 20 patients—13 with simultaneous nephroureterectomy, 6 with distal ureteral stump positivity and 1 with urachal cancer—365 patients were included in the analysis. To predict UTUC recurrence, we examined the cancer extension pattern in cystectomy specimens and categorized them into three types: cancer located only in the bladder (bladder‐only type), cancer extending to the urethra or distal ureter (one‐extension type) and cancer extending to both the urethra and distal ureter (both‐extension type). We determined hazard ratios for UTUC recurrence for each covariate, including this cancer extension pattern.Results: Of the 365 patients, 60% had the bladder‐only type, 30% had the one‐extension type and 10% had the both‐extension type. During a median follow‐up period of 72 months for survivors, UTUC recurred in 25 of the 365 patients, with cumulative incidences of 3.7% at 5 years and 8.3% at 10 years. The median interval from cystectomy to recurrence was 65 months (interquartile range: 36–92 months). In the multivariate analysis, the extension pattern was a significant predictor of UTUC recurrence. The hazard ratios for UTUC recurrence were 3.12 (95% confidence interval [CI] = 1.15–8.43, p = 0.025) for the one‐extension type and 5.96 (95% CI = 1.98–17.91, p = 0.001) for the both‐extension type compared with the bladder‐only type.Conclusions: The cancer extension pattern in cystectomy specimens is predictive of UTUC recurrence. A more extensive cancer extension in cystectomy specimens elevates the risk of subsequent UTUC recurrence. Intensive long‐term monitoring is essential, particularly for patients with the both‐extension type.
- Open Access
The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis
Biological or immunological differences in primary lesions between synchronous and metachronous metastatic renal cell carcinoma (mRCC) have been reported. However, the association between the tumor immune microenvironment (TIME) of primary lesions and time to metastasis remains unknown. We investigated the differences in the TIME of primary lesions based on time intervals to metastasis, mainly between the synchronous group (SG; metastasis within 3 months) and metachronous group (MG; metastasis after 3 months), and its association with clinicopathological parameters in patients with mRCC. Overall, 568 patients treated first-line with vascular endothelial growth factor receptor inhibitors comprised the analysis population (SG: N = 307 [54.0%]; MG: N = 261 [46.0%]). SG had a higher proportion of patients with poor prognostic pathological feature tumors: WHO/ISUP grade 4, necrosis, lymphovascular invasion, infiltrative growth pattern, and sarcomatoid differentiation. Regarding the TIME, more immunogenic features were seen in SG than MG, with a higher PD-L1 positivity and a lower proportion of the desert phenotype. This is the first study to examine the differences in the TIME of primary lesions in patients with mRCC based on the time intervals to metastasis. The TIME of primary lesions could affect the time to metastasis.
Open AccessThe Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis
Biological or immunological differences in primary lesions between synchronous and metachronous metastatic renal cell carcinoma (mRCC) have been reported. However, the association between the tumor immune microenvironment (TIME) of primary lesions and time to metastasis remains unknown. We investigated the differences in the TIME of primary lesions based on time intervals to metastasis, mainly between the synchronous group (SG; metastasis within 3 months) and metachronous group (MG; metastasis after 3 months), and its association with clinicopathological parameters in patients with mRCC. Overall, 568 patients treated first-line with vascular endothelial growth factor receptor inhibitors comprised the analysis population (SG: N = 307 [54.0%]; MG: N = 261 [46.0%]). SG had a higher proportion of patients with poor prognostic pathological feature tumors: WHO/ISUP grade 4, necrosis, lymphovascular invasion, infiltrative growth pattern, and sarcomatoid differentiation. Regarding the TIME, more immunogenic features were seen in SG than MG, with a higher PD-L1 positivity and a lower proportion of the desert phenotype. This is the first study to examine the differences in the TIME of primary lesions in patients with mRCC based on the time intervals to metastasis. The TIME of primary lesions could affect the time to metastasis.
- 12 September 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-6
Analysis of Fast Method of Electricity Prices in Scenarios of High Penetration of Renewable Energy Resources
In order to realize a carbon-neutral society by 2050, it is necessary to ensure the large-scale introduction of renewable energy. Furthermore, from the viewpoint of the investment in power plants in the future, electricity market prices are also important factors. Therefore, various future scenarios should be analyzed to understand whether it will be possible to achieve equilibrium between electricity supply, demand and flexibility. In order to investigate future scenarios, the Unit Commitment (UC) method has been used in many studies. However, analysis of the UC problem using the Mixed Integer Linear Programming (MILP) method has a heavy computational burden. This paper proposes a method to reduce the calculation time significantly. In the proposed method, the binary variables in the MILP are replaced by real variables in the UC and calculated using the Linear Programming Relaxation method. In the numerical experiment, the calculation accuracy for market prices is validated for scenarios of high penetration of renewable energy.
- 12 September 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-6
Analysis of Fast Method of Electricity Prices in Scenarios of High Penetration of Renewable Energy Resources
In order to realize a carbon-neutral society by 2050, it is necessary to ensure the large-scale introduction of renewable energy. Furthermore, from the viewpoint of the investment in power plants in the future, electricity market prices are also important factors. Therefore, various future scenarios should be analyzed to understand whether it will be possible to achieve equilibrium between electricity supply, demand and flexibility. In order to investigate future scenarios, the Unit Commitment (UC) method has been used in many studies. However, analysis of the UC problem using the Mixed Integer Linear Programming (MILP) method has a heavy computational burden. This paper proposes a method to reduce the calculation time significantly. In the proposed method, the binary variables in the MILP are replaced by real variables in the UC and calculated using the Linear Programming Relaxation method. In the numerical experiment, the calculation accuracy for market prices is validated for scenarios of high penetration of renewable energy.